Loading clinical trials...
Loading clinical trials...
An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target
Conditions
Interventions
tofacitinib
Locations
1
United States
AARDS Research, Inc.
Aventura, Florida, United States
Start Date
May 1, 2015
Primary Completion Date
December 1, 2017
Completion Date
March 20, 2018
Last Updated
July 5, 2019
NCT07484243
NCT06647069
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
Norman B. Gaylis, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions